SCHEMBL4478137

SCHEMBL4478137

CN(C)c1ccc(CNC(=O)[C@H]2CN(C(=O)CN)CCN2S(=O)(=O)c2ccc(C(F)(F)F)cc2)cc1

nearest known ligand 0.49

Predicted protein targets (top 15)

geneUniProtsupporting neighboursconfidence
KCNH2 Q12809 2/20 0.49
MMP1 P03956 5/20 0.46
MMP9 P14780 4/20 0.46
MMP13 P45452 4/20 0.46
FKBP1A P62942 1/20 0.44
MMP3 P08254 2/20 0.44
MMP7 P09237 2/20 0.44
POLB P06746 1/20 0.43
GAA P10253 1/20 0.43
ADAM17 P78536 1/20 0.42
TRPA1 O75762 3/20 0.42
P2RX7 Q99572 1/20 0.42
CA2 P00918 1/20 0.41
HCRTR1 O43613 1/20 0.41
HCRTR2 O43614 1/20 0.41

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
Hydrochloric Acid SCHEMBL2442416 0.99 KCNH2 (0.49) KCNH2MMP1MMP9MMP13FKBP1A
SCHEMBL2441591 0.91 KCNH2 (0.49) KCNH2MMP1MMP9MMP13FKBP1A
SCHEMBL12293512 0.89 MMP1 (0.48) MMP1MMP9MMP13FKBP1AMMP3
SCHEMBL4478023 0.89 MMP1 (0.48) MMP1MMP9MMP13FKBP1AMMP3
SCHEMBL4581363 0.88 MMP1 (0.46) MMP1MMP9MMP13FKBP1AMMP3
Hydrochloric Acid SCHEMBL2441828 0.88 MMP1 (0.49) MMP1MMP9MMP13FKBP1AMMP3
Hydrochloric Acid SCHEMBL2439899 0.88 MMP1 (0.49) MMP1MMP9MMP13FKBP1AMMP3
Hydrochloric Acid SCHEMBL2441581 0.87 MMP1 (0.47) MMP1MMP9MMP13FKBP1AMMP3
SCHEMBL12327797 0.84 KCNH2 (0.50) KCNH2P2RX7
SCHEMBL2441738 0.84 MMP1 (0.53) MMP1MMP9MMP13FKBP1AMMP3

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-20120107273-A1 NEW PIPERAZINE COMPOUND AND USE THEREOF AS A HCV POLYMERASE INHIBITOR JAPAN TOBACCO INC. (JP) 2012-05-03 US disclosed
US-8017612-B2 therapeutic agent for hepatitis C; R)-4-(4-trifluoromethyl-benzenesulfonyl)-piperazine-1,3-dicarboxylic acid 3-(4-isopropyl-benzylamide) 1-pyridin-4-ylamide; enzyme inhibitors JAPAN TOBACCO INC. (JP) 2011-09-13 US disclosed
US-20080081818-A1 therapeutic agent for hepatitis C; R)-4-(4-trifluoromethyl-benzenesulfonyl)-piperazine-1,3-dicarboxylic acid 3-(4-isopropyl-benzylamide) 1-pyridin-4-ylamide; enzyme inhibitors JAPAN TOBACCO INC. (JP) 2008-04-03 US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20080081818-A1 therapeutic agent for hepatitis C; R)-4-(4-trifluoromethyl-benzenesulfonyl)-piperazine-1,3-dicarboxylic acid 3-(4-isopropyl-benzylamide) 1-pyridin-4-ylamide; enzyme inhibitors HAVCR2, AADAC, DNPEP KCNH2 2476/4885MMP1 511/4885MMP9 2522/4885
US-20120107273-A1 NEW PIPERAZINE COMPOUND AND USE THEREOF AS A HCV POLYMERASE INHIBITOR POLR1C, POLR2E, POLR2H KCNH2 2974/4885MMP1 626/4885MMP9 2144/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.